Loading…
← CockpitCompetitor Analysis › 6919.TW Caliway Biopharmaceuticals Co LtdOpen in the cockpit ↗

Caliway Biopharmaceuticals Co Ltd6919.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology

Taiwanese clinical-stage biotech developing injectable drugs for localized fat reduction and other aesthetic/dermatology indications.

≈ A Taiwanese peer to Allergan's Kybella developerMomentum weak 32
Mkt cap
$3.32B
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$15.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-24.1 pp
WACC 6.9%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · TWDNT$72.00
1D-3.7%
1W+2.9%
1M-6.4%
3M-30.8%
6M-25.1%
YTD-53.5%
1Y-51.0%
ATR %6.5%
52w lowhigh61.7% off high

What Caliway Biopharmaceuticals does

Taiwanese clinical-stage biotech developing injectable drugs for localized fat reduction and other aesthetic/dermatology indications.

Has no approved product, so it earns no product sales; it relies on money raised from investors and, if achieved, licensing deals with larger aesthetic-drug companies. Everything depends on trial results and regulatory approval of its injectable fat-reduction drug.

In one line: A Taiwanese peer to Allergan's Kybella developer.

Products and services

  • CBL-514 (localized fat-reduction injection)
  • Other aesthetic-medicine and inflammatory-disease pipeline

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Aesthetic/dermatology drug development

What could go right

  • Regulatory approval/commercial launch of lead candidate

What could go wrong

  • Clinical trial failure risk
  • Cash burn before commercialization

Moat: narrow (IP / patents). Patent-protected injectable drug candidates in a clinical-stage pipeline, unproven commercially.

Headquarters: New Taipei City, Taiwan · Founded: 2012

Named competitors

Caliway Biopharmaceuticals at a glance

Size Caliway Biopharmaceuticals (6919.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $3.32B, the 110th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$72.00 on 18 Nov 2026.

Performance Over six months the shares fell 25.1%, against +5.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 54.3% over the last twelve months (peer median +5.3%); the operating margin is -6,982.6% (peer median -2.3%).

Valuation It trades at 6,626.2× enterprise value to sales against a peer median of 8.5× (most expensive of 17).

Capital Return on invested capital runs 24.1 points below its cost of capital (6.9% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 1046919.TW 76
Six months, rebased to 100: Caliway Biopharmaceuticals against the median of its 20 peers (local-currency closes).

Caliway Biopharmaceuticals financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$16.0MNT$38.0MNT$44.4MNT$38.9MNT$12.8M
Revenue growth—-14%+14%+204%—
Gross profit-NT$17.5M-NT$4.13MNT$1.26M-NT$398,000-NT$15.7M
EBITDA-NT$1.09B-NT$677M-NT$688M-NT$486M-NT$294M
Net income-NT$611M-NT$352M-NT$589M-NT$488M-NT$286M
Free cash flow-NT$415M-NT$442M-NT$532M-NT$433M-NT$257M
Capital expenditureNT$18.2MNT$17.1MNT$11.1MNT$9.69MNT$14.2M
Total debtNT$231MNT$3.00MNT$31.6MNT$20.5MNT$28.7M

Quarterly statements and history in the cockpit →

Caliway Biopharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%ELVN002007VIRPIOVA600161IRONXERSABCLRLAY603127ADMATLXTNGXDYNRUBICON2228CRSPBAVA96886919.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Caliway Biopharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×2,000×4,000×6,000×002007VIRPIOVA600161XERSABCLRLAY603127TLXCRSP6919.TWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Caliway Biopharmaceuticals is the large dot.

Caliway Biopharmaceuticals competitors and peer comparison

Head to head with its named competitors (6919.TW vs ABBV vs EOLS vs INMD)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Caliway Biopharmaceuticals 6919.TW$3.32B-25%-54%-6,983%6,626.2×n/a
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%
Evolus EOLS$468M+7%+14%-5%1.8×n/a
InMode INMD$741M-8%+2%18%0.6×-10.8%
Galderma GALD.SW$51.9B+18%+16%19%9.7×18.0%

How Caliway Biopharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Caliway Biopharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure6919.TWPeer medianRank in peer set
1-month return-6.4%-4.6%9th lowest of 21
6-month return-25.1%+5.5%2nd lowest of 21
Distance from 52-week high-61.7%-29.3%2nd lowest of 21
Revenue growth (TTM)-54.3%+5.3%2nd lowest of 17
Operating margin-6,982.6%-2.3%lowest of 17
EV / Sales6,626.2×8.5×most expensive of 17
ROIC minus cost of capital-24.1 pp-6.2 pp6th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%11.8×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a

Questions

Who are Caliway Biopharmaceuticals's main competitors?
Named competitors: AbbVie (Allergan) (ABBV), Evolus (EOLS), Revance Therapeutics (private or unlisted), InMode (INMD), Galderma (GALD.SW). The cockpit's measured peer set (industry) also includes Enliven Therapeutics (ELVN), Hualan Biological Engineering (002007.SZ), Virbac (VIRP.PA), Iovance Biotherapeutics (IOVA), Beijing Tiantan Biological Products (600161.SS), Disc Medicine (IRON).
Is Caliway Biopharmaceuticals expensive compared with its peers?
On ev / sales it trades at 6,626.2× against a peer median of 8.5×, most expensive of 17 in its peer set.
How has Caliway Biopharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -25.1% against +5.5% for the median peer; over one year -51.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.